Search Medical Condition
Please enter condition
Please choose location from dropdown

Herston, Australia Clinical Trials

A listing of Herston, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (406) clinical trials

A Study of Biomarker-Directed Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with ...

Phase

4.36 miles

Learn More »

Efficacy and Safety Study of Tenalisib (RP6530) a Novel PI3K / Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),

Phase

4.36 miles

Learn More »

An Investigational Immuno-therapy Study to Assess the Safety Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung ...

Phase

4.36 miles

Learn More »

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Dose escalation of AB928 in combination with AB122 will be assessed in participants with advanced malignancies. In this dose escalation combination study participants will receive oral administration of AB928 as well as iv infusion of AB122. Overall duration of treatment will depend on how well the treatment is tolerated. Treatment ...

Phase

4.36 miles

Learn More »

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

This phase III study is designed to evaluate the role of IL-1 inhibition in combination with docetaxel in subjects with advanced NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy. The randomized III part will be preceded by a safety run-in part in which the recommended dose of the combination ...

Phase

4.36 miles

Learn More »

Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3

Patients with Bronchiolitis Obliterans syndrome (BOS) 2 & 3 (25) will be matched 1:2 BOS 0 patients with similar demographics such as age, gender, BMI, time post transplant and renal dysfunction.Patients fitting inclusion/exclusion criteria once they have given informed consent will complete questionnaires on quality of life (QOL), any sleep ...

Phase N/A

4.37 miles

Learn More »

Phase N/A

4.37 miles

Learn More »

Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction

This is a phase 2, multi-center, randomized study (n=82, 1:1 MSC:placebo) where consented patients will receive 4 intravenous doses of IMP over a period of 2 weeks. Patients must provide written informed consent and meet the all Inclusion Criteria and none of the Exclusion Criteria to be eligible. Screening procedures ...

Phase

4.37 miles

Learn More »

Breathlessness Exertion and Morphine Sulphate

Background: Three hundred thousand (300,000) Australians are breathless at rest or on minimal exertion, often for years, despite optimal treatment of the underlying cause(s). This includes more than 70,000 people who are too breathless to leave their homes often for long periods of time. Underlying causes for such severe and ...

Phase

4.37 miles

Learn More »

High Intensity Interval Training in Fibrotic Interstitial Lung Disease

Interstitial lung disease (ILD) is a chronic lung condition characterized by scarring of lung tissue. This stiffening of the lungs impairs breathing and reduces the amount of oxygen being delivered throughout the body limiting the ability to perform daily and physical activity. Around two-thirds of people with ILD have fibrotic ...

Phase N/A

4.37 miles

Learn More »